Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.9 USD | -10.06% | -0.66% | -26.66% |
01:51pm | Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating | MT |
07/05 | Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.66% | 5.32B | |
-2.35% | 89.33B | |
+3.29% | 41.19B | |
-15.40% | 31.87B | |
+53.68% | 24.52B | |
-14.35% | 15.68B | |
-39.65% | 12.23B | |
-6.52% | 12.34B | |
-13.41% | 12.21B | |
+6.22% | 8.83B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q3 Revenue $22.1M